Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 6/20 | 0.41 |
| ▸ | CA1 | P00915 | 6/20 | 0.41 |
| ▸ | CA2 | P00918 | 6/20 | 0.41 |
| ▸ | CA9 | Q16790 | 6/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SOD1 | P00441 | 1/20 | 0.40 |
| ▸ | CD44 | P16070 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.38 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.38 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31556482 | 0.91 | HTT (0.49) | TSHRGLATRPV4CA12CA1 | |
| SCHEMBL788091 | 0.91 | HTT (0.49) | TSHRGLATRPV4CA12CA1 | |
| SCHEMBL152556 | 0.86 | SOD1 (0.47) | TSHRGLACA12CA1CA2 | |
| SCHEMBL29707985 | 0.86 | SOD1 (0.47) | TSHRGLACA12CA1CA2 | |
| SCHEMBL20182638 | 0.86 | TSHR (0.44) | TSHRGLATRPV4CA12CA1 | |
| SCHEMBL1991714 | 0.85 | TRPV4 (0.50) | TSHRTRPV4CA12CA1CA2 | |
| SCHEMBL197659 | 0.84 | TSHR (0.44) | TSHRGLATRPV4CA12CA1 | |
| SCHEMBL26512818 | 0.84 | TRPV4 (0.38) | TSHRGLATRPV4CA12CA1 | |
| SCHEMBL534192 | 0.80 | TRPV4 (0.47) | TSHRTRPV4CA12CA1CA2 | |
| SCHEMBL30161536 | 0.80 | TRPV4 (0.47) | TSHRTRPV4CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049200-B1 | NOVEL INHIBITORS OF BETA-LACTAMASE | METHYLGENE INC (CA) | 2015-04-29 | — | — | EP | disclosed |
| US-8440643-B2 | Inhibitors of beta-lactamase | METHYLGENE INC. (CA) | 2013-05-14 | — | — | US | disclosed |
| US-20100279983-A1 | NOVEL INHIBITORS OF BETA-LACTAMASE | METHYLGENE INC. | 2010-11-04 | — | — | US | disclosed |
| EP-2049200-A2 | NOVEL INHIBITORS OF BETA-LACTAMASE | MethylGene Inc. (CA) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008073142-A2 | NOVEL INHIBITORS OF BETA-LACTAMASE | MERCK & CO., INC. (US) | 2008-06-19 | — | — | WO | disclosed |
| US-6617357-B2 | Administering to a patient for inhibiting cyclic nucleotide phosphodiesterases (PDEs) activity, a benzenesulfonamide compound | SMITHKLINE BEECHAM CORPORATION | 2003-09-09 | — | — | US | disclosed |
| US-20020156064-A1 | Compounds and their use as PDE inhibitors | SMITHKLINE BEECHAM CORP | 2002-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156064-A1 | Compounds and their use as PDE inhibitors | PDE3A, PDE2A, PDE5A | TSHR 2981/4885GLA 331/4885TRPV4 3140/4885 |
| US-20100279983-A1 | NOVEL INHIBITORS OF BETA-LACTAMASE | MGAM, MGAM2, PGLS | TSHR 4294/4885GLA 49/4885TRPV4 4788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.